Triple monoamine reuptake inhibitor (DA NE 5-HT)

Our opinion on this compoundEstablished, active research

51/100

Triple reuptake inhibitor with a real Phase 2 weight-loss signal, now most interesting for hypothalamic obesity research

Tesofensine has one of the more interesting origin stories in obesity pharmacology: it failed in Alzheimer’s and Parkinson’s trials, and the weight loss that showed up as an adverse event became the entire rationale for repurposing. The 2008 Phase 2 published by Astrup et al. (roughly 160 patients, 24 weeks) showed approximately 10 percent body weight reduction at 0.5 mg/day, which was genuinely impressive at the time and outpaced liraglutide at standard doses by a real margin. That signal hasn’t been retracted. The problem is that the GLP-1 and dual-incretin era has since moved the goalposts considerably, and tesofensine’s headline number looks modest against semaglutide’s 15 percent and tirzepatide’s 20-plus. What was competitive in 2008 is a different conversation in 2025.

Mechanistically, balanced inhibition across all three monoamine transporters, DA, NE, and 5-HT, with similar affinity at each site hits mesolimbic reward circuits, prefrontal satiety signaling, and hypothalamic energy expenditure pathways simultaneously. That’s not a novel mechanism class. Cocaine covers this space nonselectively, sibutramine handled two of the three legs before withdrawal, and the basic pharmacology is well-characterized. What is distinctive is the 9-day plasma half-life, which creates a steady-state profile unlike anything else in the class and is genuinely useful for chronic exposure modeling in preclinical work. That kinetic fingerprint matters if you’re designing studies around sustained central monoamine elevation.

Here’s what actually makes tesofensine worth attention for a bench investigator right now: it’s not the general obesity indication. Saniona has pivoted the development program toward hypothalamic obesity, specifically Prader-Willi syndrome and craniopharyngioma-acquired hypothalamic obesity. These are populations where the normal satiety architecture is damaged or absent, which means the GLP-1 mechanism, dependent at least partly on intact hypothalamic GLP-1R signaling and downstream circuits, may not perform as expected. A central monoamine approach that compensates for broken hypothalamic regulation rather than trying to activate it is a mechanistically distinct rationale. Small populations, yes, but thats exactly the kind of clean indication-mechanism fit that produces interpretable research questions.

What we don’t love is the Phase 3 history. Enrollment paused multiple times owing to modest cardiovascular signals, blood pressure elevation, dry mouth, insomnia, and mood changes. That safety ceiling has capped tolerable dosing in ways that limit efficacy headroom. The compound isn’t scheduled in most jurisdictions, which keeps it accessible for research, but it’s also not approved anywhere, so the evidence base stops at Phase 2 with a stalled Phase 3. Evidence quality is real but thin at the top end.

We rate tesofensine established-active rather than novel-frontier. The repurposing story is nearly two decades old, the mechanism is a known class, and the incretin wave has redefined what competitive means in metabolic pharmacology. The hypothalamic obesity angle and the monoamine probe utility for energy homeostasis research keep this above mid-range, but serious investigators should go in with clear eyes about what Phase 3 stalls mean for translational confidence.

Novelty: 42
Mechanism promise: 60
In-category differentiation: 52
Evidence quality: 48
Translational signal: 55
Research bench value: 48

Rationale The mechanism is a known class, the 2008 Phase 2 is real but 17 years old, and the GLP-1 era has moved the goalposts on general obesity efficacy; scores mid-range because the hypothalamic obesity niche and monoamine probe utility are genuine research angles, but Phase 3 stalled and differentiation against current obesity pharmacology is limited.

Triple monoamine reuptake inhibitor (DA, NE, 5-HT)

A triple reuptake inhibitor originally developed for Alzheimer’s and Parkinson’s disease and repurposed for obesity, advanced through Phase 2 with substantial body weight reduction relative to placebo.

Abstract

Tesofensine (NS2330; CAS 195875-84-4; molecular formula C17H23Cl2N; molecular weight 312.28) is a triple monoamine reuptake inhibitor developed by NeuroSearch in the 1990s as a candidate for Alzheimer’s disease and Parkinson’s disease (where dopamine reuptake inhibition was hypothesized to provide motor symptom relief without the on-off fluctuations of L-DOPA). The compound failed to demonstrate efficacy in the original Alzheimer’s and Parkinson’s indications; weight loss observed as an adverse event in the central nervous system trials motivated repurposing for obesity, with Phase 2 data published in 2008 showing approximately 10 percent body weight reduction at 24 weeks at the 0.5 mg dose, substantially greater than the comparator orlistat and meaningfully greater than the GLP-1 agonist liraglutide at typical doses. Mechanism is competitive inhibition at the dopamine, norepinephrine, and serotonin transporters with similar affinity at all three sites; the integrated effect is monoamine elevation in mesolimbic, prefrontal, and hypothalamic targets that suppresses appetite and increases energy expenditure. The compound was advanced through Phase 3 by NeuroSearch and partner Saniona for obesity but Phase 3 enrollment was paused multiple times owing to safety signals (modest blood pressure elevation, dry mouth, insomnia, mood changes) and the program has progressed slowly relative to the more recent GLP-1 class. Saniona has continued development for hypothalamic obesity (Prader-Willi syndrome and acquired hypothalamic obesity from craniopharyngioma surgery), with the rationale that the central monoamine elevation may compensate for hypothalamic dysfunction in these niche populations. The compound is not approved in any jurisdiction. Plasma half-life is approximately 9 days, suitable for once-daily oral administration with steady-state achieved over 4 weeks.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1341Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: Triple monoamine reuptake inhibitor (DA NE 5-HT)

Tesofensine

Abstract

Read the full monograph